Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Appraisal of cancer drugs: a comparison of the French health technology assessment with value frameworks of two oncology societies

Published:2019-06-26 Issue:4 Volume:20 Page:405-409
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Li J.¹²³,Vivot A.¹⁴,Alter L.⁵,Durand-Zaleski I.³⁶

Affiliation:

1. Clinical Epidemiology Unit, Greater Paris University Hospitals (AP-HP), Paris, France

2. Judge Business School, University of Cambridge, Cambridge, UK

3. Faculty of Medicine, Paris XII University, Créteil, France

4. UMR1153 Epidemiology and Statistics Sorbonne Paris Cité Research Center (CRESS), INSERM, University Paris Descartes, Paris, France

5. Department is Oncology Business Unit, LILLY FRANCE, Neuilly-sur-Seine, France

6. URC Eco IdF, Greater Paris University Hospitals (AP-HP), Paris, France

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1635458

Reference23 articles.

1. Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

2. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

3. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs

4. French Health Technology Assessment of Antineoplastic Drugs Indicated in the Treatment of Solid Tumours: Perspective for Future Trends

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review;Journal of Health Economics and Outcomes Research;2023-06-20

2. HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review;Journal of Health Economics and Outcomes Research;2023-06-20

3. Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement;The European Journal of Health Economics;2023-03-30

4. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies;Frontiers in Medical Technology;2022-09-05

5. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019;International Journal of Cancer;2022-07-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3